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Abstract
In contrast to other cancer types, melanoma incidence has been increasing over the last 
50 years, and while it still represents less than 5% of all cutaneous malignancies, melanoma 
accounts for the majority of skin cancer deaths, due to its propensity to metastasize. Whilst 
melanoma most commonly affects the skin, it can also arise in mucosal surfaces, the eye, and 
the brain. In order for new therapies to be developed, a better understanding of the genetic 
landscape, signalling pathways and tumour-microenvironmental interactions are needed. This 
is where animal models are of critical importance. The mouse is the foremost used model of 
human melanoma. Arguably this is due to its plethora of benefits as a laboratory animal, 
however, it is important to note that unlike humans, melanocytes are not present at the dermal-
epidermal junction in mice and mice do not develop melanoma without genetic manipulation. 
In contrast, there are numerous case reports of animals that spontaneously develop 
melanoma, ranging from sharks and parrots to hippos and monkeys. In addition, there are also 
several domesticated and laboratory-bred animals that spontaneously develop melanoma or 
UV-induced melanoma, specifically, fish, opossums, pigs, horses, cats and dogs. In this 
review, we look at spontaneously occurring animal ‘models’ of melanoma and discuss their 
relevance to the different types of melanoma found in humans.
Keywords
Melanoma, naturally occurring, UV-induced, animal model, fish, pig, cat, horse, dog.
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1. Introduction
Melanoma is a tumour that arises from uncontrolled proliferation of melanocytes 
(pigment-producing cells). Although the most common form of melanoma is cutaneous, it can 
also arise from melanocytes in the mucosal surfaces (mucosal melanoma), the eye (ocular 
melanoma), and leptomeninges (leptomeningeal melanoma). Although all subtypes of 
melanomas are derived from melanocytes and thus share the same embryonic origin and 
cellular function, the etiopathogenesis and biological behaviour of these melanoma subtypes 
are very different with distinct landscapes of genetic alterations and different metastatic routes. 
The major signalling pathways implicated in melanoma are shown in Figure 1 and the most 
commonly mutated genes for each melanoma subtype are shown in Table 1.
1. 1 Melanoma developing on sun-exposed skin
The current 4th edition of the World Health Organization (WHO) classification of skin 
tumours separates melanocytic tumours according to sun-exposure: melanoma arising in 
intermittently sun-exposed skin, melanoma arising in chronically sun-exposed skin and 
melanoma arising on sun-protected skin [1]. Chronic and intermittent ultraviolet (UV) light 
exposures are a major cause of melanoma development in sun-exposed skin, and UV-induced 
melanoma is the most common type of melanoma in pale/fair skin types (people of European 
descent), typically occurring at 30-60 years of age (or 70 years of age in cumulative sun-
induced damage cases) [2]. The degree of cumulative sun-exposure also influences the 
histological subtypes of melanoma. Melanomas on chronically sun-exposed skin are typically 
of the lentigo maligna or desmoplastic variants, while melanoma on intermittently sun-exposed 
skin is most frequently of the superficial spreading or nodular subtypes. Although cutaneous 
melanoma represents <5% of all skin malignancies, it accounts for the majority of skin cancer 
deaths [3], due to its aggressive nature and propensity to metastasise. Whilst the prognosis for 
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patients with advanced stage melanoma has undoubtedly improved in recent years, with a 
current five year survival of 52% and median survival of >60 months for  those treated with 
combination immunotherapy (Ipilimumab/Nivolumab) [4], more progress still needs to be made.
1. 2 Melanoma developing on sun-protected areas
The large group of melanomas developing on sun-protected skin includes acral 
melanoma, genital and mucosal melanoma, ocular melanoma and leptomeningeal melanoma. 
Other rare subtypes of melanoma that arise independent of UV light exposure are Spitz 
melanoma, melanoma arising in blue naevi and melanoma arising in congenital naevi. 
1.2.1 Acral melanoma
Acral melanoma arises on sun-protected sites, including the palms of the hands, soles 
of the feet, and the nail apparatus (subungal), of the middle-aged and elderly with a mean of 
around 60 years of age. Although the absolute incidence is independent of ethnicity the relative 
incidence is highest individuals with darker skin types (people of African, Middle Eastern or 
Asian ethnicity), typically occurring at 60 years of age [2]. The majority of melanomas are of 
the acral lentiginous or nodular subtype. Acral melanoma carries a particularly poor prognosis, 
as it is often detected at a more advanced stage.
1.2.2 Genital and mucosal melanoma
In comparison to cutaneous melanoma, genital and mucosal melanomas (MM) are 
much rarer, representing only 0.8-3.7% of all melanomas [5]. They are relatively more common 
in the Asian and black populations where they account for 9-22% of all melanoma cases [5]. 
This is due to the rarity of UV light associated melanoma subtypes in this patient population. 
Like acral melanomas, genital and mucosal melanomas typically occur at 60 years of age [2]. 
The majority of MMs present in the nasal cavity and the accessory sinuses, the oral cavity, 
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anorectum, vulva and vagina, but they can arise in almost every part of mucosal membranes, 
including the parotid glands, oesophagus and middle ear [6]. Histologically, they are most 
commonly of the lentiginous mucosal subtype followed by nodular melanoma. MMs are known 
to behave more aggressively with less favourable prognosis compared to other melanoma 
subtypes. Most MMs occur in occult sites, which together with the lack of early and specific 
signs, contribute to late diagnosis and poor prognosis, with a 5 year survival rate of 25-33%, 
according to disease stage and location [7]; metastasis to lungs and liver occur in 50% of cases 
with head and neck melanoma [7].
1.2.3 Ocular melanoma
Ocular melanoma (OM) is the most common primary cancer affecting the eye, and is 
classified based on the anatomic site of origin: conjunctival melanoma or uveal melanoma 
(UM). The majority of OM originates from the uvea (95%), comprising the posterior uvea 
(choroid 90% and ciliary body 5%) and the anterior uvea (iris 5%). There is a wide age 
distribution for the development of UM, with an average age of 60 years [2]. Although the 
primary tumour can be effectively surgically removed, half of all patients develop metastasis 
(typically the liver or lung) and these patients have a poor prognosis, with a median survival 
time of 4-15 months [8]. Conjunctival melanoma generally presents as a pigmented nodular 
lesion typically on the bulbar conjunctiva and often involves the limbus [9]. Approximately 20-
30% of conjunctival patients develop metastatic disease, either directly extending into the 
eyeball and orbit or more distant metastases to the lungs, brain, liver, skin, bones and 
gastrointestinal tract [10].
1.2.4 Primary melanocytic neoplasms of the central nervous system
Primary melanocytic neoplasms of the central nervous system (CNS), which can be 
divided into either benign or malignant and localised or diffuse, are presumed to arise from the 
melanocytes in the leptomeningeal tissue [11]. However, primary melanoma of the CNS is rare, 
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with only an incidence of 0.005 per million people [12] (compared to 2.8-3.1 per 100,000 people 
for cutaneous melanoma [13]), whereas secondary intracranial melanomas are more common, 
with ~10-40% of melanomas metastasizing to the CNS [14]. Meningeal melanocytomas are 
solitary, low-grade tumours with no invasion of surrounding structure, with a reported annual 
incidence of 1 case per 10 million population [15]. In contrast, meningeal melanomas are 
solitary, highly aggressive, radioresistant tumours that can metastasize, resulting in poor 
prognosis, with a reported annual incidence of 0.5 cases per 10 million population [16]. The 
diffuse presenting tumours, generally involving large expanses of the subarachnoid space, are 
meningeal melanocytosis, which is a proliferation of cytologically bland melanocytic cells, and 
meningeal melanomatosis, which is a primary melanoma of the CNS. Diffuse meningeal 
melanocytic tumours are rare and as such population-based incidence is not available, 
however, they are strongly linked with neurocutaneous melanocytosis, which is a rare disease 
that is presents before 2 years of age and is typically associated with giant congenital naevi 
[17]. The prognosis for diffuse meningeal melanocytic tumours, in the setting of 
neurocutaneous melanocytosis, is extremely poor, with no known effective treatment options 
and no reports of survivors in the literature [18].
1. 3 Melanoma of unknown primary
Melanoma of unknown primary (MUP) refers to metastatic melanoma occurring in lymph 
nodes, subcutaneous tissue, or visceral sites in the absence of a detectable primary tumour 
[19] and accounts for ~2–9% of cases of metastatic melanoma [20]. The most common clinical 
presentation of MUP is lymph node disease without clinical or radiological evidence of visceral 
involvement [19] and typically presents in the fifth and sixth decades of life [21]. The origin of 
MUP is not fully understood and explanations have included regression of primary cells at the 
site of origin (regression is found in melanoma with a frequency ranging from 10% to 35% [22]), 
misdiagnosis of the original primary cutaneous melanoma and de novo malignant 
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transformation of ectopic melanocytes in lymph nodes or other organs [19]. Interestingly, 
genomic analysis of MUPs has found they have a mutational profile more similar to cutaneous 
melanoma than that of mucosal melanoma or CNS melanoma, including mutations in BRAF 
and NRAS [23], suggesting that regression or misdiagnosis of a previous cutaneous lesion was 
the primary melanoma.
1. 4 The use of the mouse to model melanoma
In order to study basic mechanisms and pre-clinically test novel therapies, accurate 
animal models are required. The most popular animal model for melanoma research is the 
laboratory mouse, and there are numerous mouse models of cutaneous melanoma [reviewed 
in 24] and uveal melanoma [reviewed in 25], as well as a few models of mucosal melanoma 
[26] and leptomeningeal melanoma [27]. Although each model has its own distinct advantages 
and disadvantages (transgenic models, gene knockout/knockin models, xenograft models, or 
UV/carcinogen-induced models), our understanding of the molecular mechanisms of 
melanoma development in humans has been greatly improved by modelling various pathways 
in these mice [28-29]. However, it is worth mentioning that interpreting results from melanoma 
studies in mice need to take into consideration several key aspects: (i) the heterogeneity of 
melanoma in humans, which would not be recapitulated in inbred laboratory mice, (ii) the 
spontaneous development of melanoma in humans, as melanoma does not spontaneously 
occur in the mouse, and (iii) the differences in the structure of the skin between humans and 
mice, as melanocytes are located in the epidermis in humans and in the dermis in mice [30], 
meaning there is a different melanocyte microenvironment, which may account for differences 
in melanoma development and progression between the two species. Thus it is worth looking 
at animals that spontaneously develop melanoma (of all subtypes) and assessing what 
relevance they have to human melanoma as alternative animal models.
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2. Melanoma in the ‘wild’
There have been reports of melanoma spontaneously occurring in a wide range of 
species, including fish, reptiles, birds, and mammals, with some examples detailed in Table 2. 
In reptiles, tumours of pigment-producing cells of the skin are called chromatophoromas, and 
are subclassified on the basis of the type of pigment, specifically melanophoromas or 
iridophoromas. A review of chromatophoromas that arose in 26 reptiles (6 snakes, 19 lizards 
and 1 tortoise) found that 6 of the 20 melanophoromas, were classified as malignant due to the 
presence of intravascular tumour cells, visceral metastases, high pleomorphism and/or mitotic 
figures [44]. Microscopically, most of the tumours were composed of spindle cells with varying 
pigmentation and both melan A and S100 were expressed by all of the tumours (by 
immunohistochemistry) [44]. Six of the 9 reptiles that were euthanized, either immediately after 
diagnosis or following recurrence of their tumour, had visceral metastases [44]. Figure 2 shows 
a metastatic melanophoroma found at autopsy of a 60-year old red-eared slider turtle 
(Trachemys scripta elegans).
However, whilst it is of interest to see the similarities of the histological descriptions of 
these melanomas with that seen in human melanoma, these case reports demonstrate the low 
frequency of the spontaneous development of this tumour type in these animals. Indeed, 
malignant melanomas are rare in fish and extremely rare in reptilian and avian species. In 
addition, the specialised habitat required for many of these animals, makes them unfeasible 
for use as a model organism. However, there are several non-genetically-modified laboratory-
bred animals that develop melanoma (due to selective breeding of affected individuals), some 
spontaneously and others after exposure to radiation such as specific species of fish, 
opossums and pigs. In addition, there several domesticated animals in which the spontaneous 
development of melanomas is relatively common, such as the dog and horse. These animals 
offer many important advantages as ‘models’ of melanoma in humans, which are discussed 
below.
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3. Laboratory-bred animal models of spontaneously occurring melanoma
3. 1 Fish
The first fish models of melanoma were established in Xiphophorus (commonly known 
as platyfish or swordtails), which are euryhaline and freshwater fish native to Mexico and 
northern Central America. The Xiphophorus model (also known as “Gordon–Kosswig–Anders” 
melanoma) was originally introduced in the late 1920s and uses interspecies platyfish that 
spontaneously develop melanoma, in a genetically controlled manner (reviewed in [45]). The 
playtfish (X. maculatus) parental line carries the spotted dorsal (Sd) macromelanophore 
pigmentation pattern. These spots are non-malignant melanocytic lesions or 
hyperpigmentation on the dorsal fin, and the macromelanophore pattern is considered a bengin 
precursor to melanoma. This is controlled by the pigment-cell-specific oncogene locus Tu (for 
tumour), the oncogenic activity of which is suppressed by the tumour suppressor locus R (for 
regulator). In the classical cross, platyfish, which carry Tu and R, are crossed with swordtails 
(X. hellerii), which carry neither locus and thus have no pigmentation pattern. When the 
resulting F1 hybrids are backcrossed with swordtails, 25% of progeny inherit the Tu oncogene 
as heterozygotes, but not the R locus, and these Tu/- hybrids develop spontaneous, highly 
malignant melanoma (Figure 3).
Positional cloning identified the melanoma-inducing Tu locus as a novel receptor 
tyrosine kinase termed Xmrk (Xiphophorus melanoma receptor tyrosine kinase) [46], that 
originated from a tandem gene duplication of the Xiphophorus EGFR (epidermal growth factor 
receptor) gene, and is the fish orthologue of human EGFR. The oncogenic activity of Xmrk 
depends on its overexpression, which correlates with the aggressiveness of the melanoma, as 
Xmrk expression increases with malignancy [47]. Xmrk carries two activating mutations that 
result in a constitutively active receptor whose signals elicit a variety of cellular responses 
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including proliferation, anti-apoptosis and cell motility, that ultimately result in melanoma 
development (reviewed in [45]). Interestingly, despite being oncogenic Xmrk has been 
maintained for several million years in the Xiphophorus melanoma model, and clues for the 
positive selection were found in experiments with Xiphophorus cortezi that showed females 
prefer males with an enhanced Sc pattern [48], Xmrk males (regardless of Sc phenotype) were 
more aggressive than Xmrk-deficient (wildtype) males [49] and collections of males from four 
natural populations of these fish found that those with malignant melanomas were significantly 
larger than both Xmrk males without melanomas and Xmrk-deficient males [50]. Based on 
genetic linkage analyses the Cdkn2ab gene was proposed as the critical component of the 
tumour suppressor R locus (so named due to 55% amino acid homology with the human 
tumour suppressor genes CDKN2A and CDKN2B that are frequently mutated in melanoma) 
[51]. Cdkn2ab has been subsequently shown to have a melanoma‐suppressive function in 
Xmrk transgenic medaka models [47], but it is not clearly established if the R locus is Cdkn2ab.
The relevance of the Xiphophorus model to human melanoma stems from the fact that 
Xmrk, being an oncogenic version of the well-studied EGFR, uses several signalling pathways 
already known for the EGFR, including the Ras/Raf/MAPK (mitogen-activated protein kinase) 
pathway that is commonly mutated in human melanomas (reviewed in [52]). This fish model 
significantly contributed to the understanding of the importance of the receptor tyrosine kinase 
(RTK)–Ras–MAPK pathway signalling in melanoma, along with engineered melanoma models 
in mice, cell line studies and human chromosomal rearrangements (reviewed in [53]). Similarly, 
Xmrk also induces the PI3K signalling pathway, and it was the discovery of the constitutive 
activation of STAT5 correlating with the aggressiveness of melanoma in Xiphophorus [54], that 
prompted investigation of the role of STAT5 human melanoma [55]. 
Xiphophorus also represent a relevant model as they are one of only a few animal 
models for which the induction of melanomas can occur by exposure to UV radiation alone and 
studies in these fish were important for proving the role that solar UV-B radiation plays in the 
formation of cutaneous melanoma [56]. More recently, gene expression profiling of melanomas 
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produced in these fish showed the high-expressing Xmrk Xiphophorus melanomas share 
transcriptomic features and molecular functions of highly proliferative, dedifferentiated human 
melanoma [57]. 
3.2 Opossum
The gray short-tailed opossum, Monodelphis domestica is a small (~100 g) pouchless 
marsupial native to South America that has been maintained in outbred colonies in laboratories 
since 1978 (reviewed in [58]). Monodelphis has the distinction of being the only naturally 
existing mammal, other than humans, known to be susceptible to melanoma in response to UV 
radiation alone. It was long suspected that UV radiation was involved in the etiology of 
cutaneous melanoma in humans, however, it was studies in Monodelphis that proved that UV 
radiation can act as a complete carcinogen for melanoma induction, and that DNA damage is 
involved in melanoma formation [59]. UV (primarily UV-B)-exposed Monodelphis develop a 
variety of hyperplastic and neoplastic skin lesions on their shaved back, including malignant 
melanoma [60] and UV exposure of neonatal Monodelphis results in the development of 
naevus with further repeated UV exposure into adulthood (up to 45 weeks of age) resulting in 
progression to malignant melanoma with metastases to lymph nodes [61].
Genetic characterisation of the UV-induced melanocytic hyperplasias and melanomas 
of Monodelphis found that altered levels of expression of CDKN2A and ARF genes are 
associated with the etiology of melanoma formation and progression in these animals [62]; 
both CDKN2A and ARF are major contributors to melanoma initiation and progression in 
humans [2]. In addition, Monodelphis have both DNA photoactivated excision repair and 
ubiquitous excision repair mechanisms, as do humans [63]; in contrast, an absence of 
photoactivation of UV‐induced pyrimidine dimers is detectable in mouse epithelial cells in vivo 
[64]. Studies in Monodelphis have also shown that SPF 15 sunscreen is effective in 
dramatically reducing the incidence of melanocytic naevi [65], and since it was demonstrated 
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that 43% of Monodelphis with nevi progress to malignant melanoma in middle-to-late adulthood 
[66], this makes Monodelphis a model of sunscreen-mediated melanoma prevention. 
 
3.3 Pig
The spontaneous occurrence of melanoma in pigs is generally very low; during a 5-
month study of pig carcasses from two abattoirs, only 220/747,014 (0.03%) had gross 
cutaneous and lymph node lesions suggestive of melanoma [67]. Interestingly, however, 
174/176 of the cutaneous lesions submitted for histological analysis were spontaneously 
regressing melanomas (the remaining 2 were non-regressing melanomas). Through selective 
breeding to increase the incidence of melanoma in pig breeds, three models of hereditary 
melanoma in pigs have been established: the Sinclair miniature swine, the Munich miniature 
swine troll and the Melanoma-bearing Libechov minipig, each showing congenital or early 
postnatal development of melanoma and spontaneous regression associated with 
depigmentation.
3.3.1 Sinclair miniature swine
The Sinclair miniature swine was derived from the Hormel miniature pig at the Hormel 
Institute in the USA. The first observation of cutaneous melanoma in the Sinclair miniature 
swine strain was in 1967 at an incidence of 21% [68] however with subsequent selective 
breeding the incidence is now at ~60%, with black coat-colour pigs developing multiple 
congenitally- or postnatally-appearing skin lesions (exophytic, flat, ulcerated, locally necrotic) 
and red-coat color developing no tumours [69]. 
The Sinclair miniature swine melanoma model has numerous features in common with 
melanoma in humans. Firstly, they develop benign melanocytic lesions (benign naevi) that are 
capable of malignant transformation (superficial spreading melanoma or nodular melanoma) 
with metastatic spread of the deeply invasive tumors (to lymph nodes and visceral organs, 
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mainly lungs and liver), which is analogous to the progression of melanoma seen in humans 
[70] (Figure 4). Secondly, these melanomas are capable of undergoing spontaneous 
regression, as has been reported in some human melanoma patients (Figure 4). In addition, 
the fact that several melanoma lesions can progress and regress simultaneously in the same 
pig [71] suggests that tumor heterogeneity may play a significant role in the natural history of 
swine melanoma, similar to that see in humans. The Sinclair swine melanoma model also 
affords the unique opportunity to perform sequential biopsies on a single lesion (due to the 
large size of the swine melanomas) and similarly, the opportunity to perform biopsies on 
progressing and regressing tumours. Finally, there is a heritable component to the 
development of melanomas as seen with some melanomas in humans, although as yet the 
exact genetic determinants responsible are not yet known (structural alterations in 
chromosomes 2, 3, 6, 7, and 12 may represent the initial step of melanoma development [72]). 
Spontaneous regression of melanomas due to a tumour-related immune response has 
been reported in human patients. In the Sinclair miniature swine, the regression of the 
melanoma occurs in a two-phase process, with the first phase (typically occurring at 2 months 
of age) characterised by a massive macrophage infiltration, followed by the second phase 
(typically occurring at 4 months of age) characterized by lymphocyte infiltration and complete 
elimination of melanomas [73]. The tumour-infiltrating lymphocytes in the second stage were 
identified as cytotoxic (CD4-/CD8+), and were found at much higher levels than in the peripheral 
blood, suggesting that the cytotoxic T-lymphocytes play the main role in the final elimination of 
the melanoma. However, as antibodies against melanoma antigens were found in the pigs with 
spontaneously regressing melanoma, usually preceding or appearing together with tumor 
regression and depigmentation, an antibody-mediated immune response directed against 
common antigens presented by both malignant and normal melanocytes may also play a role 
[74]. The spontaneous regression has also been found to be associated with defective 
telomerase activity [75] and increased sensitivity of the melanoma cells to apoptosis [76]. 
Page 13 of 53
http://mc.manuscriptcentral.com/jpath
The Journal of Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
14
3.3.2 Munich miniature swine troll
The Munich miniature swine (MMS) troll is historically the second swine model with 
hereditary melanoma, although it is not as widely used as the other 2 models. It was 
established at the University of Munich in Germany in 1986, using a melanoma-bearing boar 
with two unaffected sows from the herd originally developed from the Hanford and the 
Columbian miniature swine [77]. Similar to the other pig models, selective breeding has led to 
a high incidence of malignant tumors (~70%), benign melanocytic lesions are also observed, 
the skin lesions are already present at both or appear within 2 months after birth, and complete 
spontaneous regression of melanomas accompanied by hair and skin depigmentation occurs. 
Interestingly, elevated expression of porcine endogenous retroviruses were detected in 
melanomas and pulmonary metastasis-derived cell cultures from the MMS troll [78], and 
upregulated transcription and expression of human endogenous retrovirus (HERV) group 
HERV-K(HML-2)-encoded proteins has been reported in human melanomas [79]. However, it 
is not clear what role this retroviral material plays in the onset and/or promotion of 
tumourigenesis [80].
3.3.3 Melanoma-bearing Libechov minipig 
The generation of the melanoma-bearing Libechov minipig model was first started in 
1966 at the Czech Academy of Sciences in Libechov by importing Goettingen miniature swine 
from the University of Goettingen in Germany that were cross-bred with Minnesota miniature 
pigs from the Hormel Foundation in the USA and Vietnamese pigs from German zoos [81]. 
Subsequent years of cross-breeding with pigs of several commercial meat breeds and 
Vietnamese pigs (to maximize genetic variability) produced a population of more than 
genetically heterogeneous 2,000 descendants, with the first few black piglets with melanoma 
being observed in 1989. Selective breeding of melanoma-bearing animals confirmed the 
genetic predisposition to melanoma, with an incidence of ~50% and this new pig model was 
termed the melanoma-bearing Libechov minipig (MeLiM) [82-83]. Subsequent breeding 
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programs have increased the melanoma incidence to ~80%, with tumour devitalization being 
applied to the very affected pigs to increase their survival and allow their use in breeding [84]. 
Reflecting the multi-hybrid nature of this strain, MeLiM pigs show variability in coat 
colour, with the black pigs being most affected by melanoma. The black pigs develop three 
types of melanocytic skin lesions (superficial spreading melanoma, nodular melanoma or 
unclassified melanoma) and display a lesion continuum from lentigo to metastatic melanomas 
[85]. The metastases typically occur in the lymph nodes, lungs and spleen (with heavily affected 
animals bearing metastases in other visceral organs). The MeLiM melanomas share a lot of 
similarity with human melanomas, both in terms of their biochemistry and 
immunohistochemical characteristics. For example, the deep-black pigmentation of the 
tumours is due to the high concentration of melanosomes with a high proportion of melanin 
[86], as found in the Sinclair swine [87] and human nodular melanoma [88]. Similarly, increased 
expression of key proteins in melanoma diagnosis and malignancy are found to be elevated in 
both MeLiM melanomas and human melanomas, such as S100, RACK1 and Tenascin C 
(reviewed in [84]). In addition, mass spectrometry analysis of growing MeLiM melanoma tissue 
showed high concentrations of zinc (due to elevated metallothionein content) [89], which has 
also been reported in human melanomas [90].
Similar to the Sinclair miniature swine model, the development of melanoma in the 
MeLiM model is hertiable and polygenic. Although the precise genetic determinants not yet 
known, a genome-wide association study (GWAS) revealed several loci on chromosomes 2, 
5, 7, 8, and 16 showing significant associations with melanoma occurrence and progression, 
and comparison to human melanoma GWAS results indicated shared association signals at 
CDKAL1 and TERT loci but also nearby CCND1, FTO, PLA2G6 and TMEM38B-RAD23B loci 
[91]. Further similarities with the Sinclair miniature swine model include the cutaneous 
melanoma lesions being present either at birth or within first 2 months of life, and the lesions 
either progressing (developing extensive metastasis that leads to death within the first 3 
months of life) or spontaneously regressing (with associated skin and bristle depigmentation) 
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[84]. The spontaneous regression occurs asynchronously between the different lesions on the 
animal (regression is usually completed around 6-12 months of age) and the depigmentation 
can sometimes spread to the entire body, suggesting activation of immune cells against an 
antigen common to normal melanocytes as well as melanoma cells [82]. Spontaneous 
regression in both the Sinclair miniature swine and MeLiM melanomas represent a promising 
immunological model for monitoring immune cells participating in anti-melanoma reaction. 
Double-positive (DP) T-lymphocyte (CD4+/CD8high) populations of effector/memory ab T-cells 
(both in the peripheral blood (PBL) and within the tumour (TIL)) have been reported to expand 
in MeLiM animals during melanoma regression and it is postulated they are involved in the 
regression process [92], although this in in contrast to the Sinclair miniature swine model which 
found the populations of DP lymphocytes were generally consistent in all TIL and PBL 
populations examined [93]. Nevertheless, a significant increase of DP lymphocytes has also 
been reported in human melanomas and metastases [94].
Finally, the role of the microbiome in melanoma development has been able to be 
studied in MeLiM piglets. The number of Fusobacteria was higher in melanoma samples 
compared to healthy skin and also in progressing melanomas compared to regressing ones 
[95]. Interestingly, the abundance of Fusobacteria in the gut is connected with colorectal cancer 
development and progression in humans (reviewed in [96]), thus it will be of interest to see if 
the skin microbiome also plays a role in melanoma development or progression in humans.
4. Domesticated animal models of spontaneously occurring melanoma
4. 1 Horse
In horses, skin tumours are the most common among neoplasms, with up to 15% of all 
equine skin tumours being melanocytic [97]. Although >90% of these melanocytic tumours are 
benign at initial presentation, if left untreated, up to two-thirds can progress to overt malignancy 
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and are able to undergo widespread metastasis [97-99]. The vast majority appear in grey or 
white horses, usually at or before the age of 5 years which corresponds to the time in their life 
when their coat colour changes [97-98; 100-101]. A review of the pathological characteristics 
of equine melanoma (based on a retrospective study of 53 cases) proposed 4 manifestations 
of equine melanotic disease: melanocytic nevus, discrete dermal melanoma (benign and 
malignant forms), dermal melanomatosis, and anaplastic malignant melanoma [102]. The 
range of intradermal naevi seen in horses resembles those seen in humans, with common 
melanocytic naevi, cellular blue naevi and combined cellular blue naevi, showing 
histopathological features in common with their human counterparts [103]. Although discrete 
dermal melanoma and dermal melanomatosis were described as distinctly separate entities by 
Valentine [102], these are generally histologically indistinguishable, presenting as indistinct, 
heavily pigmented tumour cells in the deep dermis, thus it seems equally probable that these 
diagnoses exist as a continuum [104]. Interestingly, in contrast to melanomas in solid-coloured 
horses, which although rarer, are characterised by high malignancy and early metastases, 
melanomas in grey horses tend to have an extended period of benign growth, prior to malignant 
transformation and metastasis [97; 105]. Nevertheless, grey and white horses are associated 
with the development of dermal melanomatosis such that beyond the age of 15 years, at least 
80% of grey horses will have melanomas at some location [94]. Similar to human melanoma, 
equine melanomas are typically positive for the S-100, PCNA, HMB-45, Ki-67, T-311 and CD44 
markers by immunohistochemistry [101]. In addition, RACK1 expression, which was originally 
found to characterise malignant melanocytic lesions in the MeLiM model and, later in human 
melanomas, has also been found to be effective in distinguishing benign melanocytic tumours 
from melanomas in horses [106].
The complex inheritance of melanoma and coat/skin pigmentation (grey level, vitiligo 
grade, and speckling grade) in grey horses has been shown to be primarily due to the effects 
of a 4.6-kb duplication in intron 6 of the STX17 (syntaxin 17) gene; this constitutes a cis-acting 
regulatory mutation that has melanocyte-specific effects (possibly due to the fact that it affects 
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an enhancer that encodes binding sites for the microphthalmia-associated transcription factor 
(MITF), which regulates melanocyte development) [107-108]. Both STX17 and the 
neighbouring NR4A3 (nuclear receptor subfamily 4, group A, member 3) gene are 
overexpressed in melanomas from grey horses. Elevated STX17 is associated with constitutive 
activation of the ERK pathway in melanocytic cells [109], thus highlighting the similarities to 
human melanoma in which the MAPK/ERK pathway is also involved in melanomagenesis. 
Similarly, just as MC1R plays an important role in regulating skin pigmentation and melanoma 
growth in humans, and expression of agouti signalling protein (ASIP), known MC1R antagonist, 
slows B16-F10 melanoma growth and increases survival times in mice [110], grey horses 
carrying a loss-of-function mutation in ASIP have a higher incidence of melanoma [107], 
suggesting that increased melanocortin-1 receptor signalling promotes melanoma 
development in grey horses, as it does in humans. 
Melanoma nodules occur most frequently underneath the tail and at high rates in the 
peri-anal region, lips, and eyelids, with some also noted in the vulva [105; 111] (Figure 5). As 
many of these areas are near mucosal epithelium, equine melanomas may represent a model 
for mucosal melanoma in humans. Next-generation sequencing of equine melanomas that 
originated from mucosal-like (perineum, perianal region, prepuce, vulva, or ventral tail) or 
mucocutaneous sites (near the eyes or mouth, and show both mucosa and haired skin) were 
whole-exome sequenced, as well as some from cutaneous sites (haired skin only) and other 
sites (urinary bladder wall muscle and the parotid gland), found that similar to human mucosal 
melanomas, most equine melanomas had less than 5 mutations/Mb [112], unlike UV-
associated human subtypes such as superficial spreading and nodular melanoma [113]. In 
addition, the most prominent driver genes were NRAS and TP53, as has been reported in 
human mucosal melanoma samples [112]. Both species also showed mutations in PTEN and 
KIT, as well as a few cases with BRAF mutations. Interestingly however, equine melanoma 
cases from mucosal-like or mucocutaneous sites, showed a landscape of driver genes that 
was less populated than that seen for human mucosal melanoma, and there were fewer 
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recurrently mutated genes in common with human mucosal melanoma, with no mutations 
found in SF3B1, ATRX or NF1 [112]. The equine cutaneous melanomas had no point mutations 
or indels in known human melanoma driver genes (apart from one having an NRASQ61R 
mutation) [112], and as such they show some similarities to pigmented epithelioid 
melanocytoma (‘animal-type melanoma’), a rare type of melanoma in humans that does not 
carry mutations in genes frequently mutated in cutaneous melanoma [114].
4.2 Cat
Melanoma of any site in the cat is rare, with only 4 melanomas found out of 3,145 feline 
diagnoses at the Animal Medical Center in New York [115]. However, in contrast to other 
domesticated species such as dogs and horses, cats develop intraocular melanoma more 
frequently than cutaneous melanoma [116]. In a study of 29 feline melanomas over an 11 year 
period, 19 melanomas were intraocular, with the iris being the most common area of 
involvement, metastasis occurring in 63% of these cases, and 62.5% of the cats requiring 
euthanasia ~5 months post-diagnosis [116]. Indeed, iris melanoma is the most frequent feline 
intraocular tumour (Figure 6), with only rare cases of choroidal melanoma being reported [117]. 
This is in contrast to humans, where most intraocular (uveal) melanomas originate in the 
choroid (with iris melanoma being rare); these do not usually spread and are associated with 
a >95% 5-year relative survival rate. Nevertheless, these feline ocular melanomas may offer 
an alternative to the other animal models of ocular melanoma, which suffer the limitations that 
they do not replicate the critical behaviour of the disease in humans, specifically spontaneous 
occurrence and concurrent metastasis (reviewed in [118]).
4.3 Dog
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Melanocytic tumours are relatively common in the dog, and are typically malignant; a 
study of 2,350 cases of melanocytic tumours found 70% were malignant melanomas and 30% 
were benign tumours (melanocytomas) [119]. The anatomical locations of melanoma in the 
dog are oral (62% of cases), cutaneous (27%), digit (6%), ungual (4%) and ocular (1%) [119]. 
Interestingly, the correlation with malignancy varies at each site, with 84-100% of oral, digit and 
ungual melanocytic tumours being malignant (melanoma), in contrast to only 43% and 29% of 
cutaneous and ocular melanocytic tumours being malignant (respectively) [119].
4.3.1 Mucosal melanoma
Canine melanomas of the oral cavity occur mostly on the gingiva, but also on the lips, 
tongue, tonsils, palate, and oropharynx (Figure 7a) [119-120]. Spontaneous anal sac, intestinal 
and intranasal melanoma have also been reported, but these mucosal sites are much more 
rare [121]. Similar to humans, epidemiological studies have shown certain breeds more prone 
(at a higher-risk) to develop oral melanoma, with Poodles, Golden Retrievers, Labradors, 
Rottweilers and Yorkshire terriers representing 50% of the cases [121]. Similar to human 
mucosal melanoma, canine oral melanoma is an aggressive tumour showing local 
invasiveness and a high propensity to metastasize (to regional lymph nodes and lungs) [122], 
with reported median survival times of 3-24 months (depending on stage and treatment) [119]. 
Further parallels with their human counterpart is the fact that canine melanomas are resistant 
to chemotherapy and radiation therapy [123]. There are also similarities between the species 
in terms of response to therapy. Clinical trials showed that patients with metastatic mucosal 
melanoma can benefit from treatment with the immunotherapy regimes of Nivolumab (targeted 
PD-1) alone or in combination with Ipilimumab (targeting CTLA-4) [124] and similarly, a rat-dog 
chimaeric anti-PD-L1 monoclonal antibody was well tolerated and showed some clinical 
efficacy in the treatment of canine oral malignant melanoma with a response rate of 14.3% 
[125]. In addition, the use of human genes has also proved beneficial in treating canine oral 
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melanoma. For example, in a phase II clinical trial using allogeneic whole-cell vaccination, a 
canine melanoma cell line transfected with human gp100, killed by irradiation and intradermally 
administered to dogs with malignant melanoma, found objective evidence of tumour regression 
in 17.6% of cases, with dogs experiencing tumour control surviving significantly longer (337 
days) than dogs having no response (95 days) [126]. Similarly, intratumoral administration of 
the human CD94L gene was evaluated in a phase I clinical trial in four dogs with oral melanoma 
and in three of the dogs, a 12-58% reduction of tumour burden was reported, with no adverse 
effects observed [127]. Finally, a bacterial plasmid DNA vaccine encoding the human 
tyrosinase antigen (OnceptTM) is licensed for the adjuvant treatment of stage II and III canine 
oral melanoma after loco-regional control and is currently awaiting USDA approval for use in 
horses with melanoma. However, it should be noted that there is controversy about its efficacy 
as some studies have observed responses in dogs with macroscopic disease and suggested 
the vaccine could be considered as palliative treatment in dogs with stage IV disease [128], 
whilst others have found that dogs who received the vaccine did not achieve a greater 
progression-free survival, disease-free interval or median survival time than dogs that did not 
receive the vaccine [129].
A study that compared the histopathological features of human mucosal melanoma and 
canine oral melanoma found analogous architectural features were important for diagnosis and 
staging of the melanoma in both species [130]. Interestingly, both human and canine mucosal 
melanomas included the range of epithelioid, spindloid, mixed epithelioid/spindloid, or small 
round blue cell melanocyte morphologies [130]. Also noteworthy was the frequent presence of 
a lentiginous intra-epithelial component in the canine melanomas, which is a feature known to 
precede invasive melanomas in humans that subsequently metastasize, thus indicating a 
similar pathway of progression in the dog [130]. 
At the molecular level, there are many similarities of canine oral melanoma with human 
mucosal melanoma. Next-generation sequencing of canine oral melanomas revealed they had 
less than 5 mutations/Mb, similar to human mucosal and equine mucosal melanomas [112]. In 
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addition, the most prominent driver genes were NRAS and TP53, as has been reported in 
human mucosal melanoma samples, with both species also showing mutations in NF1, PTEN, 
KRAS and BRCA2 [112; 131]. Importantly, both species show involvement of the MAPK and 
PI3K/AKT pathways in mucosal melanoma formation and progression [112; 131-132], with 
constitutive pathway activation and similar sensitivity to AZD6244 and rapamycin observed in 
both in human melanoma and canine oral melanoma cell lines [133], suggesting that canine 
oral melanoma could be a good model for human mucosal melanoma. Although they did not 
show any mutations in other drivers of mucosal melanoma frequently in human patients, such 
as SF3B1 and ATRX, suggesting that these canine cancers may not represent a faithful model 
for the subset of human mucosal melanoma patients with mutations in these genes. Yet, some 
canine oral melanomas showed mutations in EIF1AX (G9V and R13C), an essential translation 
initiation factor that is mutated in human uveal melanoma [8] and meningeal melanocytic 
tumours [134], with the same N-terminal amino acid substitutions at conserved sites G9 and 
R13 also having been found in multiple other human tumours (COSMIC database: 
COSM6908971, COSM5899335) [112]; thus the canine oral melanomas have helped to 
identify the importance of these conserved regions in human tumourigenesis. In addition, 
cross-species comparative copy number analysis found that the most significant deletion in 
human mucosal melanoma samples was a deletion at 15q15.1, which is a region syntenic to a 
significant deletion in canine oral melanomas found on canine chromosome 30; both species 
harboured BUB1B, KNSTRN and B2M within this deletion regions and these genes are 
frequently altered in human tumours [112]. Similarly, both MDM2  and SMO were found to be 
amplified in human mucosal melanomas and canine oral melanomas, with these genes having 
known roles in cutaneous melanoma and a range of cancers, respectively [112]. In addition, a 
recent study looking at long non-coding RNAs (lncRNAs) in canine oral melanomas found one 
down-regulated (SOX21-AS) and two up-regulated (CASC15 and ZEB2-AS) differentially 
expressed lncRNAs (“onco-lncRNAs”), that have been shown to be differentially expressed in 
a range of human cancers [135]. 
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4.3.2 Cutaneous melanoma
Cutaneous melanocytic tumours in dogs are usually dermal in origin and are typically 
benign, referred to as melanocytomas [136]. The most common sites for benign cutaneous 
melanomas are the face (near the eyelids), trunk, and extremities, and malignant melanoma is 
found most frequently on the head, ventral abdomen, and scrotum, with metastases primarily 
occurring to the lymph nodes and lungs [136]. Cutaneous melanoma occurs more commonly 
in dogs with heavily pigmented skin, with Schnauzers and Scottish terriers at increased risk 
[137], which is in contrast to cutaneous melanoma in humans where individuals of light/fair skin 
are at increased risk.  
There is limited data available on the somatic alterations of canine cutaneous 
melanoma. One study took a candidate gene approach with 20 cutaneous melanomas and 
found no variants mutations in the key melanoma drivers, specifically BRAF, NRAS, PTEN, 
KIT, GNAQ,  and CDK4  [119], whereas another study on 2 dogs found one carried an NRAS 
mutation and one carried KRAS, TP53 and KIT mutations [138]. These reports, taken together 
with the fact that most canine cutaneous melanocytic tumours are benign and occur on hair-
bearing skin, thus are not linked to UV-light exposure, suggest these canine cutaneous 
melanomas arise from a distinct mechanism, different from that of most human cutaneous 
melanomas, and as such may be of more relevance to acral melanomas or other rare 
categories of dermal melanomas in humans [2].
4.3.3 Ocular melanoma
Melanocytic tumours are the most common ocular neoplasms in dogs, and arise most 
frequently in the anterior uvea; a study of intraocular melanocytic tumours in 244 dogs reported 
the anterior uvea as the tumour site in 85% of cases, with the limbic area and choroid 
accounting for 13 and 5%, respectively [139]. Similar to cutaneous melanocytic tumours, most 
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intraocular melanocytic tumours in dogs are benign (‘benign uveal melanoma’; Figure 7b), with 
reports of malignancy ranging from 15-30%, and those with metastatic behaviours accounting 
for ~4% [136]. The prognosis for dogs with histologically benign uveal melanoma is excellent, 
however, those with malignant uveal melanoma have significantly shorter lifespans [139]. 
Interestingly, expression profiling using a 12-gene assay has been shown to reliably distinguish 
metastasising from non-metastasising uveal melanomas in humans [140], and four of these 
genes (HTR2B, FXR1, LTA4H, and CDH1) have also been found to be overexpressed in 
metastasising canine uveal melanoma [141].
4.3.4 Acral melanoma
Melanoma is the second most common digital tumour in dogs, accounting for 15-17% 
of neoplasias of the digits [142-143]. Similar to human acral melanoma, which arises on the 
plantar surface of the foot, palms of hands, and fingers, canine acral melanoma arises on the 
footpad or nail bed. Studies have shown that most canine melanocytic tumors of the digits are 
malignant (49-86% of cases) and all nail bed melanocytic tumors are malignant [119]. As with 
other forms of melanoma in the dog, the development of melanoma in the digits of dogs are 
over-represented in some breeds, such as the Scottish terrier, Schnauzer, Beauce shepherds, 
and Rottweilers [142-143]. These tumours are locally aggressive, with bone lysis occurring in 
40-58% of cases and a high propensity to metastasize, with lymph node or lung metastasis 
found in 30-40% of cases at the time of presentation [142]. To date, only 3 melanomas from 
the digits of dogs have been characterized at the genomic level with 2 having KRAS mutations 
and 1 having an NRAS mutation [131]. 
4.3.5 Leptomeningeal melanoma
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There has been little research into leptomeningeal melanoma/melanomatosis in dogs, 
most probably due to the rarity of the disease. Indeed, there is only one published report of 
primary CNS melanoma in a dog; an 11-year old Black and Tan Coonhound with disseminated 
melanoma involving the right femoral bone marrow, lung, multiple lymph nodes, and adrenal 
gland, with diffuse infiltration of the leptomeninges of the brain and spinal cord, and in light of 
the lesion distribution that resembled leptomeningeal melanomatosis in humans, the diagnosis 
was given as primary leptomeningeal melanomatosis with multiorgan metastasis [144]. Similar 
to humans, secondary (metastatic) CNS melanoma is more common than primary CNS 
melanoma; post-mortem studies of dogs with secondary intracranial tumours found them to be 
malignant melanomas in ~3.4% of cases [145-146].
5. Conclusion
The key feature(s) of each animal as a ‘model’ of melanoma in humans is listed in Table 
3. No one animal is the perfect model, however, the spontaneous nature of the development 
of melanoma and its metastatic spread in the platyfish/swordtail, opossum, miniature pig, 
horse, cat and dog, as well as the genetic heterogeneity of the latter three species, and the 
additional advantage of a shared microenvironmental exposures in companion animals, surely 
makes these animals attractive candidate models. 
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Table 1. Summary of key genetic alterations of the different melanoma classes.
Sun status High 
CSD
Low 
CSD
Sun protected areas
Tissue Cutaneous Acral Mucosal Uveal CNS
Oncogene 
activation
NRAS
BRAF1
KIT
BRAF
NRAS
BRAF
NRAS
GNAQ
KIT
CCND1 
(amp)
NRAS
KIT
BRAF
SF3B1
CCND1 
(amp)
GNAQ
GNA11
CYSLTR2
PLCB4
SF3B1
GNAQ
GNA11
CYSLTR2
PLCB4
SF3B1
NRAS2
Tumour 
suppressor 
gene loss
NF1
TP53
CDKN2A
PTEN
TP53
CDKN2A
PTEN
NF1
CDKN2A
NF1
PTEN
TP53
CDK4
BAP1 BAP1
Others TERT 
(prom)
TERT 
(prom)
TERT 
(amp)
TERT 
(amp)
EIF1AX EIF1AX
Abbreviations: Amp, amplification; CNS, central nervous system; CSD, cumulative sun 
damage; Prom; promoter mutations. 1The BRAF mutation is not the typical V600E variant. 
2There is a strong link to NRAS mutations in cases of childhood melanomas and 
neurocutaneous melanocytosis.
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Table 2. Some examples of the wide range of species in which spontaneously 
occurring melanoma or melanocytoma has been reported. 
Animal Clinical 
presentation
Diagnosis and histopathology 
report
Outcome Ref
Nurse shark
(Ginglymostoma
cirratum)
A 5.5-yr history of a 
6-cm black, raised 
nodular skin lesion 
located on the right 
side of the proximal 
tail.
Cutaneous melanoma. The 
biopsy comprised interlacing 
streams of neoplastic spindle cells 
with scant eosinophilic cytoplasm 
and vesicular nuclei with 
prominent nucleoli. A few of the 
cells contained melanin. No 
vascular invasion was noted.
Euthanized for 
systemic illness 
approximately 4.5 
months after diagnosis 
(although no evidence 
of metastasis found on 
histopathologic 
evaluation of the skin 
and viscera)
31
Haller's round 
ray
(Urobatis halleri)
Presented with 
multiple black raised 
nodular masses on 
the dorsal surface. 
Cutaneous malignant 
melanoma. The masses were 
composed of proliferative sheets 
of melanocytes exhibiting mild 
anisocytosis and anisokaryosis.
Approximately 2 
months following the 
biopsy, the ray 
became acutely 
anorexic and was 
found dead. 
32
Coral trout
(Plectropomus 
leopardus)
20/136 of line caught 
coral trout from two 
locations in the Great 
Barrier Reef Marine 
Park (in 2010-12) 
showed a dark 
growth lesion 
covering <10% to the 
entire body. 
Melanosis and melanoma. The 
lesions showed a tumourous 
appearance of disorganised
pleomorphic cells containing 
melanosomes, consistent with 
melanophorous-
macromelanophorous 
polymorphic melanoma (MMPM).
N/A. 33
Florida pine 
snake
(Elaphe 
obsoleta 
rossalleni)
Presented with a 
black dermal tumour, 
dorso-laterally in the 
posterior third of the 
body. 
Malignant melanoma. The 
melanotic cells were polyhedral 
and uniformly round or nearly 
round. The vesicular nuclei 
occupied most of the cellular 
space and the nucleoli were 
prominent. The scanty amount of 
protoplasm was heavily 
impregnated with melanin 
granules. Widespread metastasis.
Two months after 
tumour excision, 
further small black 
tumours appeared in 
various parts of the 
skin and the general 
condition of the snake 
began to deteriorate; it 
died soon after.
34
Mandarin duck
(Aix 
galericulata)
Presented with 
several small 
multinodular masses 
on the dorsal surface 
of the upper bill. 
Metastatic malignant 
Melanoma. The tissue consisted 
of multiple nests and lobules of 
neoplastic melanocytes (with 
prominent areas of necrosis). The 
lymphoid tissues contained nests 
and individual neoplastic 
melanocytes.
Two months later, the 
tumour had enlarged 
considerably. The 
duck developed 
severe dyspnea and 
was euthanatized.
35
Macaroni 
penguin
(Eudyptes 
chrysolophus)
Presented with a 
caseous and necrotic 
mass that engulfed 
the upper beak and 
extended into the 
rostra sinuses. 
Malignant melanoma. The tissue 
contained an infiltrative, deeply 
pigmented melanocytic neoplasm 
that extended from superficial to 
deep dermal regions and had 
effaced normal tissue 
architecture.
The penguin exhibited 
dyspnea as a result of 
invasion of the tumour 
into the rostral 
sinuses, and was 
immediately 
euthanised.
36
Rabbit
(Oryctolagus 
cuniculus)
Presented with an 
irregular black mass 
(4 × 3 × 2 cm) on the 
skin of scrotum, with 
ulceration and 
bleeding. 
Cutaneous malignant 
melanoma. The tumour cells 
were positive for a number of 
melanocyte markers (HMB-45, 
PNL2, Melan A, and S100) and 
Ki-67.
The perioperative 
period concluded with 
no problems, however, 
despite subsequent 
clinical progress, the 
rabbit died after two 
weeks due to 
metastasis.
37
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Pygora goat
(Capra 
aegagrus 
hircus)
Presented with a 
recurrent ulcerated, 
black-pigmented, 2.5 
cm mass at the base 
of the left horn. 
Malignant melanoma. The 
masses consisted of moderately 
pleomorphic, polyhedral to spindle 
cells containing variable amounts 
of dark brown intracytoplasmic 
pigment granules. Multiple black 
foci of metastasis observed in the 
liver.
While restraining the 
goat for physical 
examination the left 
horn broke off at the 
base with minimal 
force. Due to the poor 
condition of the goat it 
was immediately 
euthanized. 
38
Huacaya 
alpaca
(Vicugna pacos)
Presented with a 
chronic, non-healing 
wound involving the 
left external nostril. 
Metastatic mucocutaneous 
melanoma. Malignant melanoma 
was diagnosed by histology of 
biopsy specimens. At post-
mortem, numerous masses 
present throughout the body were 
composed of spindloid to 
polygonal cells with indistinct cell 
borders and moderate amounts of 
cytoplasm containing abundant 
melanin. 
The alpaca was 
euthanized 10 days 
after the diagnosis on 
the basis of the poor 
prognosis and rapid 
clinical deterioration.
39
Pygmy 
hippopotamus
(Choeropsis 
liberiensis)
Presented with 
multiple raised and 
pigmented skin 
masses. 
Dermal malignant melanoma 
and concurrent melanocytoma. 
Initial impression smears of one 
ulcerated lesion were consistent 
with inflammation however, 
subsequent histopathological 
findings from a skin biopsy 
revealed an underlying malignant 
melanoma.
There was no sign of 
recurrence 34 months 
post-surgery (no lymph 
node involvement).
40
African lion
(Panthera leo)
Presented with a 4 
month history of left 
maxillary lip swelling. 
Examination showed 
a pigmented mass at 
the level of the left 
maxillary canine 
tooth. 
Dermal malignant melanoma. 
Histopathologic evaluation of the 
biopsies revealed a malignant 
dermal melanoma with no 
evidence of metastasis.
The lion received 
radiotherapy and 
immunotherapy 
treatments.
41
Aberdeen 
Angus cow
(Bos taurus)
Presented with a 
large, pedunculated 
cutaneous mass 
protruding from the 
left flank fold and an 
enlarged left pre-
femoral lymph node. 
Congenital amelanotic 
melanoma with nodal 
metastasis. Histologic 
examination revealed a 
homogeneous population of 
neoplastic cells staining positively 
for S100 and melan A.
Two months later, the 
calf became acutely 
recumbent and was 
euthanized after 
clinical examination 
revealed widespread 
metastasis.
42
Cynomolgus 
monkey
(Macaca 
fascicularis)
A pigmented raised 
mass (2 cm 
diameter) at the 
dorsal aspect of the 
neck.
Cutaneous melanocytoma. 
Histologically, the mass was 
composed of poorly demarcated, 
heavily pigmented melanocytes 
diffusely infiltrating the dermis. 
The neoplastic cells were fairly 
uniform round to polygonal in 
shape and arranged in packets, 
supported by a fibrovascular 
stroma. The nuclei were mostly 
round and lacked nuclear atypia.
Not reported. 43
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Table 3. Key features of each animal as a ‘model’ of melanoma in humans.
Animal Key features as a model
Platyfish/
Swordtail
 Melanoma arises from the EGFR pathway (uses Ras/Raf/MAPK 
signalling)
 Melanoma incidence controlled by a pigment-cell-specific oncogene 
locus and a tumour suppressor locus
 Model of UV radiation-induced melanoma
Gray short-
tailed opossum 
 Model of UV radiation-induced melanoma
 Model of sunscreen-mediated melanoma prevention
Miniature pig  Opportunity to study the entire spectrum of melanoma formation, 
from benign lesions to malignant transformation to metastatic spread
 Model of spontaneous regression of melanomas
Horse  Melanomas under the tail and in the peri-anal region, lips and eyelids 
are models of mucosal melanoma
 Driver genes in these mucosal melanomas: NRAS, TP53, PTEN, KIT 
and BRAF
Cat  Melanomas of the uvea are a model of uveal melanoma
Dog  Melanomas of the oral cavity are a model of mucosal melanoma
 Driver genes in these mucosal melanomas: NRAS, TP53, PTEN, 
NF1, KRAS, and BRCA2
 MAPK and PI3K/AKT pathways involved in mucosal melanoma 
formation and progression
 Melanomas of the footpad or nail bed are models of acral melanoma
 Clinical trials are performed in dogs with melanoma 
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Figure legends
Figure 1. The two major signaling pathways implicated in melanoma. Commonly mutated 
genes underlined. Receptors are shown in blue, proteins in the PI3K/AKT pathway are in 
yellow, proteins in the MAPK/ERK pathway are in green, proteins in the GNAQ/GNA11 
pathway are in pink and proteins that have inhibitory roles in these pathways are in red.
Figure 2. Metastatic melanophoroma in a red-eared slider turtle. (A, B) Multifocal malignant 
melanophoromas on the shell (circle). (C, D) The lesions invaded through the shell (circle) into 
the peritoneal cavity (arrows). The photographs were kindly provided by Luke Haydock, 
Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada.
Figure 3. Melanoma in a Xiphophorus. (A) Macroscopic photo of a platyfish/swordtail 
backcross hybrid (Tu+/-, R-/-) with a large pigmented melanoma in the posterior and on the 
pectoral fin (arrows). (B-D) Images of H&E-stained sections of a large exophytic melanoma 
that covers the surface of the skin (circle), while heavily pigmented melanoma cells can be 
seen infiltrating the muscle (arrows) (25x, 100x and 200x magnification, respectively).
Figure 4. Melanomas in Sinclair miniature pigs. (A) A cutaneous melanoma on the flank 
(arrow). (B) A regressed cutaneous melanoma showing areas of skin depigmentation (arrow). 
(C) Large cutaneous melanomas on the belly and inner hind limb (arrows). (D) Hepatic 
metastases from a cutaneous melanoma (arrows). The photographs were kindly provided by 
Derek Brocksmith, Sinclair BioResources, Missouri, USA.
Figure 5. Metastatic melanoma in a horse. (A) Multiple melanomas located under the tail base 
(circle) that metastasized to the lungs and mediastinum around the heart. Shown are thoracic 
metastases (B; arrows) and metastases on the pleural surface of the ribs (C; arrows). The 
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photographs were kindly provided by Laura Bassel, Department of Pathobiology, University of 
Guelph, Guelph, Ontario, Canada.
Figure 6. Uveal melanoma in a cat. A diffuse iris melanoma (arrow). The photograph was 
kindly provided by Chantale Pinard, Department of Clinical Studies, University of Guelph, 
Guelph, Ontario, Canada. 
Figure 7. Oral and uveal melanomas in dogs. (A) A primary melanoma in the soft palate (inset), 
that invaded into oropharynx (arrow). The photographs were kindly provided by Laura Bassel, 
Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada. (B) A benign 
uveal melanoma (melanocytoma) in the iris (arrow). The photograph was kindly provided by 
Chantale Pinard, Department of Clinical Studies, University of Guelph, Guelph, Ontario, 
Canada. 
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Figure 1. The two major signaling pathways implicated in melanoma. Commonly mutated genes underlined. 
Receptors are shown in blue, proteins in the PI3K/AKT pathway are in yellow, proteins in the MAPK/ERK 
pathway are in green, proteins in the GNAQ/GNA11 pathway are in pink and proteins that have inhibitory 
roles in these pathways are in red. 
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Figure 2. Metastatic melanophoroma in a red-eared slider turtle. (A, B) Multifocal malignant 
melanophoromas on the shell (circle). (C, D) The lesions invaded through the shell (circle) into the 
peritoneal cavity (arrows). The photographs were kindly provided by Luke Haydock, Department of 
Pathobiology, University of Guelph, Guelph, Ontario, Canada. 
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Figure 3. Melanoma in a Xiphophorus. (A) Macroscopic photo of a platyfish/swordtail backcross hybrid 
(Tu+/-, R-/-) with a large pigmented melanoma in the posterior and on the pectoral fin (arrows). (B-D) 
Images of H&E-stained sections of a large exophytic melanoma that covers the surface of the skin (circle), 
while heavily pigmented melanoma cells can be seen infiltrating the muscle (arrows) (25x, 100x and 200x 
magnification, respectively). 
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Figure 4. Melanomas in Sinclair miniature pigs. (A) A cutaneous melanoma on the flank (arrow). (B) A 
regressed cutaneous melanoma showing areas of skin depigmentation (arrow). (C) Large cutaneous 
melanomas on the belly and inner hind limb (arrows). (D) Hepatic metastases from a cutaneous melanoma 
(arrows). The photographs were kindly provided by Derek Brocksmith, Sinclair BioResources, Missouri, USA. 
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Figure 5. Metastatic melanoma in a horse. (A) Multiple melanomas located under the tail base (circle) that 
metastasized to the lungs and mediastinum around the heart. Shown are thoracic metastases (B; arrows) 
and metastases on the pleural surface of the ribs (C; arrows). The photographs were kindly provided by 
Laura Bassel, Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada. 
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Figure 6. Uveal melanoma in a cat. A diffuse iris melanoma (arrow). The photograph was kindly provided by 
Chantale Pinard, Department of Clinical Studies, University of Guelph, Guelph, Ontario, Canada. 
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Figure 7. Oral and uveal melanomas in dogs. (A) A primary melanoma in the soft palate (inset), that 
invaded into oropharynx (arrow). The photographs were kindly provided by Laura Bassel, Department of 
Pathobiology, University of Guelph, Guelph, Ontario, Canada. (B) A benign uveal melanoma (melanocytoma) 
in the iris (arrow). The photograph was kindly provided by Chantale Pinard, Department of Clinical Studies, 
University of Guelph, Guelph, Ontario, Canada. 
338x190mm (54 x 54 DPI) 
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